Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd.’s latest financial statements audited by Somekh Chaikin, a member firm of KPMG International, indicate a fair presentation of the company’s financial position up to December 31, 2023, following U.S. GAAP. The firm expressed a going concern regarding NeuroSense’s ability to continue, due to recurring and expected future losses. Additionally, a switch was made from International Financial Reporting Standards to U.S. GAAP for the company’s 2023 financial statements.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
